PT - JOURNAL ARTICLE AU - Oscar Hou In Chou AU - Jing Ning AU - Raymond Ngai Chiu Chan AU - Cheuk To Chung AU - Helen Huang AU - Kenrick Ng AU - Edward Christopher Dee AU - Sharen Lee AU - Apichat Kaewdech AU - Tong Liu AU - Fengshi Jing AU - Bernard Man Yung Cheung AU - Gary Tse AU - Jiandong Zhou TI - Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study AID - 10.1101/2022.08.16.22278847 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.16.22278847 4099 - http://medrxiv.org/content/early/2022/08/17/2022.08.16.22278847.short 4100 - http://medrxiv.org/content/early/2022/08/17/2022.08.16.22278847.full AB - Background The association between sodium glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) are currently unknown.Methods This was a retrospective population-based cohort study including type-2 diabetes mellitus (T2DM) patients treated with either SGLT2I or DPP4I between 1st January 2015 and 31st December 2019 in Hong Kong. Patients with concurrent DPP4I and SGLT2I usage were excluded. The primary outcomes were NAFLD and HCC. The secondary outcomes included cancer-related mortality and all-cause mortality. Propensity score matching (1:1 ratio) was performed using the nearest neighbour search. Univariable and multivariable Cox regression was applied to identify significant predictors. Competing risks models and multiple approaches using the propensity score were performed.Results This cohort included 62699 patients with T2DM, amongst which 22154 patients were on SGLT2I and 40545 patients were on DPP4I. After matching (44308 patients), 1090 patients developed new-onset NAFLD (Incidence: 4.6; 95% Confidence interval [CI]: 4.3-4.9) and 187 patients developed HCC (Incidence: 0.8; 95% CI: 0.7-0.9). Overall, SGLT2I was associated with lower risks of NAFLD (Hazard ratio [HR]: 0.39; 95% CI: 0.34-0.46), and HCC (HR: 0.46; 95% CI: 0.29-0.72) compared to DPP4I after adjustments. SGLT2I was also associated with lower risks of cancer-related mortality (HR: 0.29; 95% CI: 0.23-0.37) and all-cause mortality (HR: 0.28; 95% CI: 0.25-0.31). However, amongst patients with hepatitis B virus infection, SGLT2I was associated with higher risks of HCC (HR: 3.28; 95% CI: 1.21-8.90). The results were consistent in competing risk models and different matching approaches.Conclusion SGLT2I was associated with lower risks of NAFLD, and HCC compared to DPP4I after propensity scores matching and adjustments.Lay summary The association between two antidiabetic medications, SGLT2I and DPP4I, and the risks of fatty liver disease and liver cancer have not been explored. In our study, SGLT2I was associated with a lower risk of fatty liver disease and liver cancer compared to DPP4I amongst patients with type 2 diabetes. However, DPP4I was associated with lower risks of liver cancer compared to SGLT2I among patients with hepatitis B virus infectionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementECD is funded in part through the Cancer Center Support Grant from the National Cancer Institute (P30 CA008748). The other authors received no funding for the research, authorship, and/or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Joint Chinese University of Hong Kong New Territories East Cluster Clinical Research Ethics Committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAn anonymised version without identifiable or personal information is available from the corresponding authors upon reasonable request for research purposes.